Casey Quinn1, Colin Young2, Jonathan Thomas2, Mark Trusheim2. 1. Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. Electronic address: caquinn@mit.edu. 2. Center for Biomedical Innovation, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Abstract
OBJECTIVES: To estimate, at the indication level, durable gene and cellular therapy new product launches in the United States through 2030, and the number of treated patients. METHODS: A statistical analysis of clinical trials pipeline data and disease incidence and prevalence was conducted to estimate the impact of new cell and gene therapies. We used Citeline's® Pharmaprojects® database to estimate the rates and timing of new product launches, on the basis of the phase of development, duration in phase, and probability of progression. Disease incidence and prevalence data were combined with estimates of market adoption to project the size of reimbursed patient populations. RESULTS: We project that about 350 000 patients will have been treated with 30 to 60 products by 2030. About half the launches are expected to be in B-cell (CD-19) lymphomas and leukemias. CONCLUSIONS: Cell and gene therapies promise durable clinical benefit from a single treatment course. High upfront reimbursement for these products means that the total costs could exceed what the healthcare system can manage. This creates a need for precision financing solutions and new reimbursement models that can ensure appropriate patient access to needed treatments, increase affordability for payers, and sustain private investment in innovation.
OBJECTIVES: To estimate, at the indication level, durable gene and cellular therapy new product launches in the United States through 2030, and the number of treated patients. METHODS: A statistical analysis of clinical trials pipeline data and disease incidence and prevalence was conducted to estimate the impact of new cell and gene therapies. We used Citeline's® Pharmaprojects® database to estimate the rates and timing of new product launches, on the basis of the phase of development, duration in phase, and probability of progression. Disease incidence and prevalence data were combined with estimates of market adoption to project the size of reimbursed patient populations. RESULTS: We project that about 350 000 patients will have been treated with 30 to 60 products by 2030. About half the launches are expected to be in B-cell (CD-19) lymphomas and leukemias. CONCLUSIONS: Cell and gene therapies promise durable clinical benefit from a single treatment course. High upfront reimbursement for these products means that the total costs could exceed what the healthcare system can manage. This creates a need for precision financing solutions and new reimbursement models that can ensure appropriate patient access to needed treatments, increase affordability for payers, and sustain private investment in innovation.
Authors: Alexander Ring; Björn Grob; Erik Aerts; Katharina Ritter; Jörk Volbracht; Bettina Schär; Michael Greiling; Antonia M S Müller Journal: Ann Hematol Date: 2022-06-27 Impact factor: 4.030
Authors: Renaud Heine; Frederick W Thielen; Marc Koopmanschap; Marie José Kersten; Hermann Einsele; Ulrich Jaeger; Pieter Sonneveld; Jorge Sierra; Carin Smand; Carin A Uyl-de Groot Journal: Hemasphere Date: 2021-01-28
Authors: Koippallil Gopalakrishnan Aghila Rani; Mohamad A Hamad; Dana M Zaher; Scott McN Sieburth; Navid Madani; Taleb H Al-Tel Journal: Expert Opin Drug Discov Date: 2020-12-28 Impact factor: 6.098